Telehealth prescribing rules for controlled substances: what changed, and what it means for ADHD and anxiety care

Pandemic-era flexibilities let telehealth providers prescribe controlled substances without an in-person visit first. The rules governing that flexibility have kept shifting since.

Prescribing controlled substances — a category that includes stimulant medications for ADHD, several anti-anxiety medications, and certain sleep medications, among others — traditionally required an in-person medical evaluation under federal law, specifically to prevent the kind of prescribing abuse the original rule was designed to guard against. Pandemic-era emergency flexibilities suspended that in-person requirement for telehealth prescribing, and that suspension has been repeatedly extended rather than allowed to lapse, given how central telehealth had become to access for these specific conditions by the time each extension deadline approached.

The rules have kept shifting in the years since rather than settling into a final, permanent framework, with regulators periodically proposing more permanent replacement rules — generally including some tightened requirements like periodic in-person evaluation for longer-term controlled substance prescribing via telehealth — that have then been delayed or revised again before taking full effect, leaving both patients and telehealth providers navigating real ongoing uncertainty about the durable long-term rules.

This has mattered enormously in practice for a few specific patient populations: adults newly diagnosed with ADHD who increasingly seek care through telehealth-only platforms, patients in rural or underserved areas without convenient access to an in-person specialist for these conditions, and patients on stable, long-term controlled substance treatment who've relied on telehealth continuity of care rather than periodic in-person visits.

For anyone currently receiving controlled substance prescriptions through a telehealth-only provider, staying aware that the underlying regulatory flexibility remains subject to change — and asking the telehealth provider directly about their specific compliance plan and whether an in-person visit will eventually be required — is a reasonable practical step given how unsettled this specific area of telehealth regulation has remained.

This article is general health information, not medical advice, and doesn’t replace evaluation by your own physician. Talk to a doctor about anything specific to your own diagnosis or treatment.

More in Health Technology

Pulse oximeters: how they work and their real accuracy limits Continuous glucose monitors for non-diabetics: worth it?Sleep tracking rings vs. wrist wearables: what's actually measured

Telehealth prescribing rules for controlled substances: what changed, and what it means for ADHD and anxiety care

Pandemic-era flexibilities let telehealth providers prescribe controlled substances without an in-person visit first. The rules governing that flexibility have kept shifting since.

This article is general health information, not medical advice, and doesn’t replace evaluation by your own physician. Talk to a doctor about anything specific to your own diagnosis or treatment.